Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease

@article{Roskrow1998EpsteinBarrV,
  title={Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease},
  author={Marie A Roskrow and Norio Suzuki and Yehudit Gan and John W. Sixbey and Catherine Y. C. Ng and Scott Kimbrough and Melissa M. Hudson and Malcolm K. Brenner and Helen E Heslop and Cliona M Rooney},
  journal={Blood},
  year={1998},
  volume={91 8},
  pages={2925-34}
}
Adoptive transfer of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) is effective prophylaxis and treatment of EBV-positive immunoblastic lymphoma in immunocompromised patients. In 50% of patients with Hodgkin's disease, the tumor cells are EBV antigen-positive and may therefore also be suitable targets for treatment with virus-specific CTLs. However, Hodgkin's disease may produce several inhibitory effects on immune induction and effector function in vivo, which may preclude… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 90 extracted citations

T lymphocyte therapy of cancer.

Physiological research • 2004
View 10 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Epstein-Barr virus, in Fields BN, Knipe DM, Howley PM (eds): Fields Virology

AB Rickinson, E Kieff
1996

Similar Papers

Loading similar papers…